| 1 |
What is the primary function of AI in the medical imaging industry?
|
To improve diagnostic accuracy and patient outcomes |
|
The core value proposition of AI in medical imaging (like radiology) is its ability to quickly analyze complex data, assist in identifying subtle findings, and reduce errors, thereby improving the accuracy of diagnoses and overall patient treatment outcomes |
The foundational premise for adopting AI in medicine is the quantifiable improvement it offers over current standards, primarily in improving diagnostic accuracy (e.g., detecting subtle lesions) and efficiency, which directly leads to better Patient Outcomes (e.g., earlier treatment, reduced mortality) |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 2 |
Which of the following is a key benefit of AI in radiology noted in the article?
|
Reduces the speed of diagnosing |
|
AI systems are designed to process and analyze medical images much faster than human radiologists can, significantly reducing the time required to generate an initial diagnosis or flag urgent cases |
One of the most immediate benefits of AI tools in radiology is speed. AI algorithms automate tasks like image prioritization, quantification, and initial screening, which reduces the turnaround time (TAT) for a diagnosis, improving clinical throughput |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 3 |
What does AI literacy refer to according to the article?
|
Understanding and knowledge of AI technology |
|
AI literacy, in the context of healthcare professionals, refers to their fundamental understanding of how AI works, its capabilities, limitations, and how it can be safely and effectively applied in clinical practice |
AI literacy is defined as the set of competencies that enables individuals to understand, evaluate, and responsibly interact with AI technologies. For clinicians, this involves understanding the principles, capabilities, and limitations of the AI tool they are using to ensure appropriate trust and safe utilization |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 4 |
Which factor is NOT listed as influencing the acceptability of AI among healthcare professionals?
|
The color of the AI machines |
|
Factors like Trust, System Integration, Understanding, and Receptiveness are psychological and practical variables that heavily influence acceptance. The machine's physical appearance or color is generally irrelevant to its clinical acceptability or performance |
Technology acceptance models (like TAM or UTAUT) focus on variables that are functionally or psychologically relevant to the user. Key factors include Perceived Usefulness (Trust, Accuracy), Perceived Ease of Use (Integration, System Understanding), and Social Influence. Physical aesthetics (like color) are not typically considered a core determinant of professional technology adoption |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 5 |
What role does social influence play in AI acceptability in healthcare according to the article?
|
Affects healthcare professionals’ decisions to use AI |
|
Social influence encompasses peer pressure, organizational norms, and the perceived usage of AI by respected colleagues or leaders, all of which significantly shape an individual healthcare professional's decision to adopt or reject new technology |
The UTAUT model explicitly includes Social Influence as a key factor. This refers to the extent to which an individual perceives that others who are important to them (e.g., peers, departmental heads) believe they should use the new technology. This perception strongly shapes their Behavioral Intention to use A |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 6 |
What is a perceived threat regarding AI usage in healthcare settings?
|
Concerns about replacing healthcare professionals |
|
A significant fear among clinicians is that AI's growing capability in diagnosis and analysis may lead to job displacement or devaluation of their professional expertise, making this a major perceived threat to acceptability |
Studies consistently show that the most common fear among medical professionals, particularly in specialties like radiology and pathology, is the risk of automation and job displacement as AI takes over analytical tasks. This fear is a major psychological barrier to acceptability |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 7 |
According to the article, what is essential for increasing AI acceptability among medical professionals?
|
Designing human-centred AI systems |
|
Systems that prioritize the needs, workflow, and interactions of the human user (the healthcare professional) are more likely to be trusted, understood, and seamlessly integrated into clinical practice, which is key to acceptability |
This philosophy dictates that technology development must focus on the user's needs, limitations, and context. In AI/Healthcare, HCD means creating tools that support the physician (e.g., via clear User Interface, explainable results) rather than replace them, fostering trust and seamless integration |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 8 |
What does the 'system usage' category of AI acceptability factors include according to the article?
|
Factors like value proposition and integration with workflows |
|
The 'system usage' category focuses on the practical application of the AI, including how beneficial it is perceived to be (Value Proposition) and how well it fits into the existing clinical routines and IT infrastructure (Integration with Workflows) |
The 'system usage' dimension relates to how the technology functions within the work environment. The AI must fit the existing workflow (Integration) and provide a clear benefit that justifies the effort of adoption (Value Proposition). If it doesn't fit, it won't be used, regardless of accuracy |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 9 |
How does ethicality impact AI acceptability among healthcare professionals?
|
Affects views on AI based on compatibility with professional values |
|
Ethical concerns (e.g., data privacy, algorithmic bias, liability) heavily influence a professional's willingness to use AI. If a system is perceived to violate core professional values like patient safety or autonomy, its acceptability will be low |
Clinicians are bound by oaths and codes of ethics (e.g., patient autonomy, do no harm). If an AI system has poor data privacy, shows clear bias, or shifts the burden of legal responsibility, it conflicts with these professional values, severely damaging the Trust needed for acceptance |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 10 |
What methodological approach did the article emphasize for future AI acceptability studies?
|
Considering user experience and system integration deeply |
|
Moving beyond simple surveys, future studies should employ qualitative and mixed-methods research to understand the complex behavioral and organizational challenges related to user experience (UX) and how well AI is practically integrated into the hospital's workflow |
Early technology acceptance studies often relied on broad surveys. Modern research emphasizes the need for qualitative and observational studies (deep dive into User Experience or UX) to uncover the nuances of how AI disrupts or integrates into complex clinical workflows—a level of detail that simple quantitative surveys often miss |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 11 |
What is the primary objective of using human embryonic stem cells in treating Parkinson’s disease?
|
To replace lost dopamine neurons. |
|
Parkinson's disease is characterized by the death of dopamine-producing neurons in the substantia nigra. The fundamental goal of cell therapy is to transplant new cells to replace these lost neurons and restore dopamine function |
Neurodegeneration and Replacement Therapy: The fundamental principle of treating PD with cell therapy is dopamine cell replacement, aiming to re-establish nigrostriatal circuitry |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 12 |
Which animal was used to test the STEM-PD product for safety and efficacy?
|
Rats |
|
Preclinical trials for neurological cell therapies typically use established rodent models (like rats or mice) of the disease before advancing to larger animals or humans. The questions explicitly refer to findings in rats |
Preclinical Models in Neuroscience: Use of established rodent models is required by regulatory bodies (e.g., FDA, EMA) to demonstrate proof-of-concept and safety before Phase I clinical trials. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 13 |
What was the duration of the preclinical safety study in rats mentioned in the article?
|
6 months |
|
While the exact time frame must come from the source, preclinical safety studies (especially for long-term cell survival) in rodents often run for several months, with 6 months being a common observation period to assess tumorigenicity and long-term biodistribution |
Regulatory guidance for cell therapy products requires extended observation (often 3-6 months in rodents) to rule out the formation of teratomas from pluripotent stem cells |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 14 |
What is the name of the clinical trial phase mentioned for STEM-PD?
|
Phase I/IIa |
|
Cell therapy trials often begin with a combined Phase I/IIa to first assess safety (Phase I) and then gain initial data on efficacy and optimal dosing in a small group of patients (Phase IIa) |
Combining these phases is efficient for novel therapies, quickly transitioning from establishing maximum tolerated dose (MTD) and safety to assessing early signs of therapeutic effect |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 15 |
How is the STEM-PD product manufactured?
|
Under GMP-compliant conditions |
|
Any product intended for human clinical trials must be manufactured according to Good Manufacturing Practice (GMP) standards to ensure quality, consistency, and safety for regulatory approval |
A set of regulatory guidelines ensuring that products are consistently produced and controlled according to quality standards appropriate to their intended use |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 16 |
According to the article, what confirmed the safety of the STEM-PD product in rats?
|
There were no adverse effects or tumor formation. |
|
A primary safety concern for stem cell therapies is the risk of cells migrating or forming tumors (teratomas). Confirmation of safety requires observing no adverse effects and no tumor formation during the observation period |
The absence of teratoma formation and signs of toxicity (adverse effects) are the gold standards for preclinical safety clearance |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 17 |
What key finding was noted in the efficacy study of STEM-PD in rats?
|
Transplanted cells reversed motor deficits in rats. |
|
Efficacy in a Parkinson's model (which primarily affects movement) is demonstrated by the reversal or significant improvement of motor deficits following the transplantation of the dopamine-producing cells |
The ultimate test of cell therapy efficacy in PD models is the recovery of function, specifically motor function, measured using behavioral tests (e.g., amphetamine-induced rotation test) |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 18 |
What specific markers were used to assess the purity of the STEM-PD batch?
|
GIRK2 and ALDH1A1 |
|
Purity assessment in dopamine neuron progenitors relies on identifying specific transcription factors and proteins. GIRK2 and ALDH1A1 are known positive markers for the mature, functional A9 dopamine neurons that are targeted for replacement |
In stem cell differentiation, specific transcription factors and protein markers confirm that the cells have correctly differentiated into the desired cell type (A9/A10 DA neurons) with high purity |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 19 |
What role do growth factors like FGF8b and SHH play in the manufacturing process of STEM-PD?
|
They are used in cell patterning for specific neural fates. |
|
FGF8b (Fibroblast Growth Factor 8b) and SHH (Sonic Hedgehog) are critical signaling molecules used in vitro (ในห้องปฏิบัติการ) to direct the stem cells to differentiate precisely into the midbrain dopamine neuron lineage—a process called cell patterning |
This is the process of using defined signaling molecules (morphogens) to guide pluripotent stem cells through developmental stages to precisely achieve a desired differentiated cell type |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 20 |
What was a key outcome measured in the preclinical trials for efficacy in rats?
|
Recovery of motor function |
|
Since Parkinson's disease severely impairs movement, the most direct and crucial measure of efficacy in animal models is the observation of recovery of motor function (e.g., in rotation tests or stepping tests) |
The key outcomes measured in animal models must be translatable to the human condition. For PD, functional motor improvement is the most critical metric |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|